Table IV.
Correlation between biomarker expression in the epithelial component of the primary tumor and prognostic factors.
| c-MYC (cyt) | c-MYC (nuc) | Ki67 | p-mTOR | p-AKT | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinico-pathological data | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive | Negative | Positive |
| HG | ||||||||||
| 1 | 1 (50.0) | 16 (20.8) | 3 (30.0) | 14 (20.3) | 15 (26.3) | 0 (0.0) | 7 (17.0) | 10 (26.3) | 2 (11.8) | 16 (25.4) |
| 2,3 | 1 (50.0) | 61 (79.2) | 7 (70.0) | 55 (79.7) | 42 (73.7) | 17 (100.0) | 34 (83.0) | 28 (73.7) | 15 (88.2) | 47 (74.6) |
| P-value | 0.38 | 0.44 | 0.02 | 0.41 | 0.33 | |||||
| LN status | ||||||||||
| Negative | 2 (100.0) | 34 (44.2) | 6 (60.0) | 30 (43.5) | 25 (43.9) | 8 (47.1) | 20 (48.8) | 17 (44.7) | 5 (29.4) | 32 (50.8) |
| Positive | 0 (0.0) | 43 (55.8) | 4 (40.0) | 39 (56.5) | 32 (56.1) | 9 (52.9) | 21 (51.2) | 21 (55.3) | 12 (70.6) | 31 (49.2) |
| P-value | 0.20 | 0.50 | 1.0 | 0.82 | 0.17 | |||||
| Stage | ||||||||||
| I | 1 (50.0) | 18 (23.3) | 4 (40.0) | 15 (21.7) | 14 (24.6) | 4 (23.6) | 14 (34.1) | 6 (15.8) | 1 (5.9) | 19 (30.2) |
| II | 1 (50.0) | 31 (40.3) | 2 (20.0) | 30 (43.5) | 21 (36.8) | 8 (47.0) | 17 (41.4) | 15 (39.5) | 11 (64.7) | 21 (33.3) |
| III | 0 (0) | 28 (36.4) | 4 (40.0) | 24 (34.8) | 22 (38.6) | 5 (29.4) | 10 (24.4) | 17 (44.7) | 5 (29.4) | 23 (36.5) |
| P-value | 0.51 | 0.29 | 0.72 | 0.08 | 0.04 | |||||
| Mitoses | ||||||||||
| 0–5 | 1 (50.0) | 30 (39.0) | 3 (30.0) | 28 (40.6) | 27 (47.3) | 2 (11.8) | 14 (34.1) | 17 (43.6) | 3 (17.6) | 29 (46.0) |
| >5 | 1 (50.0) | 47 (61.0) | 7 (70.0) | 41 (59.4) | 30 (52.7) | 15 (88.2) | 27 (65.9) | 21 (56.4) | 14 (82.4) | 34 (54.0) |
| P-value | 1.00 | 0.73 | 0.01 | 0.37 | 0.05 | |||||
| Necrosis | ||||||||||
| Absent | 1 (50.0) | 35 (45.5) | 2 (20.0) | 34 (49.3) | 27 (47.4) | 8 (47.1) | 18 (43.9) | 19 (50.0) | 7 (41.2) | 30 (47.6) |
| Present | 1 (50.0) | 42 (54.5) | 8 (80.0) | 35 (50.7) | 30 (52.6) | 9 (52.9) | 23 (56.1) | 19 (50.0) | 10 (58.8) | 33 (52.4) |
| P-value | 1.00 | 0.10 | 1.00 | 0.66 | 0.79 | |||||
| Margins | ||||||||||
| Expansive | 0 (0.0) | 36 (46.8) | 4 (40.0) | 32 (46.4) | 23 (40.4) | 12 (70.6) | 17 (41.5) | 19 (50.0) | 6 (35.3) | 30 (47.6) |
| Infiltrative | 2 (100.0) | 41 (53.2) | 6 (60.0) | 37 (53.6) | 34 (59.6) | 5 (29.4) | 24 (58.5) | 19 (50.0) | 11 (64.7) | 33 (52.4) |
| P-value | 0.50 | 0.75 | 0.05 | 0.50 | 0.42 | |||||
| ER | ||||||||||
| Positive | 1 (100.0) | 42 (55.3) | 6 (75.0) | 37 (53.6) | 32 (56.1) | 9 (52.9) | 22 (55.0) | 22 (57.9) | 12 (70.6) | 32 (52.5) |
| Negative | 0 (0.0) | 34 (44.7) | 2 (25.0) | 32 (46.4) | 25 (43.9) | 8 (47.1) | 18 (45.0) | 16 (42.1) | 5 (29.4) | 29 (47.5) |
| P-value | 1.00 | 0.29 | 1.00 | 0.82 | 0.27 | |||||
| PR | ||||||||||
| Positive | 2 (100.0) | 39 (57.4) | 4 (66.7) | 37 (57.8) | 29 (55.8) | 11 (68.8) | 22 (64.7) | 19 (52.8) | 9 (64.3) | 32 (57.1) |
| Negative | 0 (0.0) | 29 (42.6) | 2 (33.3) | 27 (42.2) | 23 (44.2) | 5 (31.2) | 12 (35.3) | 17 (47.2) | 5 (35.7) | 24 (42.9) |
| P-value | 0.51 | 1.00 | 0.40 | 0.34 | 0.76 | |||||
| HER2 | ||||||||||
| Positive | 2 (100.0) | 58 (77.3) | 8 (100.0) | 52 (75.4) | 44 (78.6) | 13 (76.5) | 31 (77.5) | 30 (78.9) | 13 (76.5) | 48 (78.7) |
| Negative | 0 (0.0) | 17 (22.7) | 0 (0.0) | 17 (24.6) | 12 (21.4) | 4 (23.5) | 9 (22.5) | 8 (21.1) | 4 (23.5) | 13 (21.3) |
| P-value | 1.00 | 0.18 | 1.00 | 1.00 | 1.00 | |||||
Cyt, cytoplasmic; nuc, nuclear; p-mTOR, phospho-mammalian target of rapamycin; p-AKT, phospho-AKT; HG, histological grade; LN, lymph node; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2.